Mitochondrial transfer therapy for inflammatory bowel disease
A novel therapeutic approach using mesenchymal stromal cells (MSCs) to transfer healthy mitochondria into intestinal organoids, potentially enhancing remission in inflammatory bowel disease by correcting mitochondrial dysfunction.
Overview
Mitochondrial transfer therapy represents a cutting-edge approach for treating inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. This innovative therapy leverages mesenchymal stromal cells (MSCs) to deliver healthy mitochondria into intestinal organoids, aiming to restore mitochondrial function and mitigate inflammation. The potential to induce mitochondrial transfer on demand could significantly enhance and prolong remission periods for patients suffering from IBD.
Technical specifications
Key features:
- Utilizes MSCs to transfer healthy mitochondria into intestinal organoids.
- Monitors mitochondrial transfer using advanced imaging techniques.
- Evaluates improvements in mitochondrial and organoid function post-transfer.
- Investigates the role of tunneling nanotubes (TNTs) and type 1 interferons in the mechanism of mitochondrial transfer.
This approach is grounded in the understanding that mitochondrial dysfunction is a critical factor in IBD, and correcting this dysfunction could offer a powerful treatment avenue. The use of MSCs and the ability to control mitochondrial transfer are central to this therapeutic strategy.
Technology readiness level
Currently at Technology Readiness Level 3, this therapy has been validated in laboratory settings using sophisticated imaging methods to monitor the MSC mitochondrial transfer process. Further validation is needed to progress towards clinical applications.
About University of Calgary
The University of Calgary is a comprehensive public research university in Alberta, Canada, known for coupling academic depth with an entrepreneurial mindset. A research and technology park adjacent to campus colocates companies with faculty labs and venture incubators, enabling shared facilities and pilot‑stage development, while co‑op and work‑integrated learning programs create direct talent pipelines. Integration with the provincial health system brings clinical care, trials, and translational research into close proximity with campus researchers. Research activity is supported by Canadian federal agencies such as NSERC, CIHR, SSHRC, and the Canada Foundation for Innovation, with additional support from provincial programs and industry consortia. A dedicated technology transfer office streamlines IP, licensing, and startup formation through standardized agreements.
delivered to your inbox.